Loading…

Interactions of Cisplatin and Daunorubicin at the Chromatin Level

Unexpectedly, the widely used anticancer agents Cisplatin (Cis-Pt) and Daunorubicin (Dauno) exhibited cell type- and concentration-dependent synergy or antagonism in vitro . We attempted to interpret these effects in terms of the changes elicited by the drugs in the chromatin, the target held primar...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2020-01, Vol.10 (1), p.1107, Article 1107
Main Authors: Firouzi Niaki, Erfaneh, Van Acker, Thibaut, Imre, László, Nánási, Péter, Tarapcsák, Szabolcs, Bacsó, Zsolt, Vanhaecke, Frank, Szabó, Gábor
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c474t-753497f29ea5dc51e2b8aa38916ca2b40e333ed8031c25bd462d0419d215dea83
cites cdi_FETCH-LOGICAL-c474t-753497f29ea5dc51e2b8aa38916ca2b40e333ed8031c25bd462d0419d215dea83
container_end_page
container_issue 1
container_start_page 1107
container_title Scientific reports
container_volume 10
creator Firouzi Niaki, Erfaneh
Van Acker, Thibaut
Imre, László
Nánási, Péter
Tarapcsák, Szabolcs
Bacsó, Zsolt
Vanhaecke, Frank
Szabó, Gábor
description Unexpectedly, the widely used anticancer agents Cisplatin (Cis-Pt) and Daunorubicin (Dauno) exhibited cell type- and concentration-dependent synergy or antagonism in vitro . We attempted to interpret these effects in terms of the changes elicited by the drugs in the chromatin, the target held primarily responsible for the cytotoxicity of both agents. We measured the effect of Cis-Pt on the levels of Dauno in different cell compartments, the effect of Cis-Pt on Dauno-induced nucleosome eviction, and assessed the influence of Dauno on DNA platination in flow- and laser scanning cytometry as well as in laser ablation-inductively coupled plasma-mass spectrometry assays. We show that the two drugs antagonize each other through a decrease of interstrand crosslinks upon co-treatment with Dauno, and also via the diminished Dauno uptake in the presence of Cis-Pt, and both effects are observed already at low Dauno concentrations. At high Dauno concentrations synergy becomes dominant because histone eviction by Dauno intercalation into the DNA is enhanced in the presence of co-treatment with Cis-Pt. These interactions may have an impact on the efficacy of combination treatment protocols, considering the long retention time of DNA adducts formed by both agents.
doi_str_mv 10.1038/s41598-020-57702-7
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6981277</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2344544885</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-753497f29ea5dc51e2b8aa38916ca2b40e333ed8031c25bd462d0419d215dea83</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EolXpD7BAkVgH_GycDVIVXpUqsYG15dhOmyq1i51U4u9xm1LKBm9szVyfuXMBuEbwDkHC7wNFLOcpxDBlWQZxmp2BIYaUpZhgfH7yHoBxCCsYD8M5RfklGBCUczjJ-RBMZ7Y1Xqq2djYkrkqKOmwa2dY2kVYnj7KzzndlrXaFNmmXJimW3q33irnZmuYKXFSyCWZ8uEfg4_npvXhN528vs2I6TxXNaJtmjNA8q3BuJNOKIYNLLiXhOZooiUsKDSHEaA4JUpiVmk6whtGtxohpIzkZgYeeu-nKtdHK2NbLRmx8vZb-SzhZi78dWy_Fwm1F3BPhLIuA2wPAu8_OhFasXOdt9CwwoZRRyjmLKtyrlHcheFMdJyAodsmLPnkRkxf75MUOfXPq7fjlJ-coIL0gxJZdGP87-x_sN04pjog</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2344544885</pqid></control><display><type>article</type><title>Interactions of Cisplatin and Daunorubicin at the Chromatin Level</title><source>PubMed (Medline)</source><source>Full-Text Journals in Chemistry (Open access)</source><source>Publicly Available Content (ProQuest)</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Firouzi Niaki, Erfaneh ; Van Acker, Thibaut ; Imre, László ; Nánási, Péter ; Tarapcsák, Szabolcs ; Bacsó, Zsolt ; Vanhaecke, Frank ; Szabó, Gábor</creator><creatorcontrib>Firouzi Niaki, Erfaneh ; Van Acker, Thibaut ; Imre, László ; Nánási, Péter ; Tarapcsák, Szabolcs ; Bacsó, Zsolt ; Vanhaecke, Frank ; Szabó, Gábor</creatorcontrib><description>Unexpectedly, the widely used anticancer agents Cisplatin (Cis-Pt) and Daunorubicin (Dauno) exhibited cell type- and concentration-dependent synergy or antagonism in vitro . We attempted to interpret these effects in terms of the changes elicited by the drugs in the chromatin, the target held primarily responsible for the cytotoxicity of both agents. We measured the effect of Cis-Pt on the levels of Dauno in different cell compartments, the effect of Cis-Pt on Dauno-induced nucleosome eviction, and assessed the influence of Dauno on DNA platination in flow- and laser scanning cytometry as well as in laser ablation-inductively coupled plasma-mass spectrometry assays. We show that the two drugs antagonize each other through a decrease of interstrand crosslinks upon co-treatment with Dauno, and also via the diminished Dauno uptake in the presence of Cis-Pt, and both effects are observed already at low Dauno concentrations. At high Dauno concentrations synergy becomes dominant because histone eviction by Dauno intercalation into the DNA is enhanced in the presence of co-treatment with Cis-Pt. These interactions may have an impact on the efficacy of combination treatment protocols, considering the long retention time of DNA adducts formed by both agents.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-020-57702-7</identifier><identifier>PMID: 31980698</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>101/58 ; 13/1 ; 13/31 ; 14/19 ; 14/34 ; 14/35 ; 14/63 ; 631/337/100/101 ; 631/337/100/1701 ; 631/67/1059/99 ; Antagonism ; Antineoplastic Agents - metabolism ; Antineoplastic Agents - pharmacology ; Antitumor agents ; Cell Line, Tumor ; Chemotherapy ; Chromatin ; Chromatin - drug effects ; Chromatin - genetics ; Cisplatin ; Cisplatin - metabolism ; Cisplatin - pharmacology ; Cytometry ; Cytotoxicity ; Daunorubicin ; Daunorubicin - metabolism ; Daunorubicin - pharmacology ; Deoxyribonucleic acid ; DNA ; DNA adducts ; DNA Adducts - drug effects ; DNA, Neoplasm - metabolism ; Dose-Response Relationship, Drug ; Drug Interactions ; Humanities and Social Sciences ; Humans ; Mass spectrometry ; Mass spectroscopy ; multidisciplinary ; Retention time ; Science ; Science (multidisciplinary)</subject><ispartof>Scientific reports, 2020-01, Vol.10 (1), p.1107, Article 1107</ispartof><rights>The Author(s) 2020</rights><rights>This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-753497f29ea5dc51e2b8aa38916ca2b40e333ed8031c25bd462d0419d215dea83</citedby><cites>FETCH-LOGICAL-c474t-753497f29ea5dc51e2b8aa38916ca2b40e333ed8031c25bd462d0419d215dea83</cites><orcidid>0000-0002-0649-7228 ; 0000-0002-1884-3853</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2344544885/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2344544885?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,44566,53766,53768,74869</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31980698$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Firouzi Niaki, Erfaneh</creatorcontrib><creatorcontrib>Van Acker, Thibaut</creatorcontrib><creatorcontrib>Imre, László</creatorcontrib><creatorcontrib>Nánási, Péter</creatorcontrib><creatorcontrib>Tarapcsák, Szabolcs</creatorcontrib><creatorcontrib>Bacsó, Zsolt</creatorcontrib><creatorcontrib>Vanhaecke, Frank</creatorcontrib><creatorcontrib>Szabó, Gábor</creatorcontrib><title>Interactions of Cisplatin and Daunorubicin at the Chromatin Level</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>Unexpectedly, the widely used anticancer agents Cisplatin (Cis-Pt) and Daunorubicin (Dauno) exhibited cell type- and concentration-dependent synergy or antagonism in vitro . We attempted to interpret these effects in terms of the changes elicited by the drugs in the chromatin, the target held primarily responsible for the cytotoxicity of both agents. We measured the effect of Cis-Pt on the levels of Dauno in different cell compartments, the effect of Cis-Pt on Dauno-induced nucleosome eviction, and assessed the influence of Dauno on DNA platination in flow- and laser scanning cytometry as well as in laser ablation-inductively coupled plasma-mass spectrometry assays. We show that the two drugs antagonize each other through a decrease of interstrand crosslinks upon co-treatment with Dauno, and also via the diminished Dauno uptake in the presence of Cis-Pt, and both effects are observed already at low Dauno concentrations. At high Dauno concentrations synergy becomes dominant because histone eviction by Dauno intercalation into the DNA is enhanced in the presence of co-treatment with Cis-Pt. These interactions may have an impact on the efficacy of combination treatment protocols, considering the long retention time of DNA adducts formed by both agents.</description><subject>101/58</subject><subject>13/1</subject><subject>13/31</subject><subject>14/19</subject><subject>14/34</subject><subject>14/35</subject><subject>14/63</subject><subject>631/337/100/101</subject><subject>631/337/100/1701</subject><subject>631/67/1059/99</subject><subject>Antagonism</subject><subject>Antineoplastic Agents - metabolism</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antitumor agents</subject><subject>Cell Line, Tumor</subject><subject>Chemotherapy</subject><subject>Chromatin</subject><subject>Chromatin - drug effects</subject><subject>Chromatin - genetics</subject><subject>Cisplatin</subject><subject>Cisplatin - metabolism</subject><subject>Cisplatin - pharmacology</subject><subject>Cytometry</subject><subject>Cytotoxicity</subject><subject>Daunorubicin</subject><subject>Daunorubicin - metabolism</subject><subject>Daunorubicin - pharmacology</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>DNA adducts</subject><subject>DNA Adducts - drug effects</subject><subject>DNA, Neoplasm - metabolism</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Interactions</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Mass spectrometry</subject><subject>Mass spectroscopy</subject><subject>multidisciplinary</subject><subject>Retention time</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNp9kMtOwzAQRS0EolXpD7BAkVgH_GycDVIVXpUqsYG15dhOmyq1i51U4u9xm1LKBm9szVyfuXMBuEbwDkHC7wNFLOcpxDBlWQZxmp2BIYaUpZhgfH7yHoBxCCsYD8M5RfklGBCUczjJ-RBMZ7Y1Xqq2djYkrkqKOmwa2dY2kVYnj7KzzndlrXaFNmmXJimW3q33irnZmuYKXFSyCWZ8uEfg4_npvXhN528vs2I6TxXNaJtmjNA8q3BuJNOKIYNLLiXhOZooiUsKDSHEaA4JUpiVmk6whtGtxohpIzkZgYeeu-nKtdHK2NbLRmx8vZb-SzhZi78dWy_Fwm1F3BPhLIuA2wPAu8_OhFasXOdt9CwwoZRRyjmLKtyrlHcheFMdJyAodsmLPnkRkxf75MUOfXPq7fjlJ-coIL0gxJZdGP87-x_sN04pjog</recordid><startdate>20200124</startdate><enddate>20200124</enddate><creator>Firouzi Niaki, Erfaneh</creator><creator>Van Acker, Thibaut</creator><creator>Imre, László</creator><creator>Nánási, Péter</creator><creator>Tarapcsák, Szabolcs</creator><creator>Bacsó, Zsolt</creator><creator>Vanhaecke, Frank</creator><creator>Szabó, Gábor</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0649-7228</orcidid><orcidid>https://orcid.org/0000-0002-1884-3853</orcidid></search><sort><creationdate>20200124</creationdate><title>Interactions of Cisplatin and Daunorubicin at the Chromatin Level</title><author>Firouzi Niaki, Erfaneh ; Van Acker, Thibaut ; Imre, László ; Nánási, Péter ; Tarapcsák, Szabolcs ; Bacsó, Zsolt ; Vanhaecke, Frank ; Szabó, Gábor</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-753497f29ea5dc51e2b8aa38916ca2b40e333ed8031c25bd462d0419d215dea83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>101/58</topic><topic>13/1</topic><topic>13/31</topic><topic>14/19</topic><topic>14/34</topic><topic>14/35</topic><topic>14/63</topic><topic>631/337/100/101</topic><topic>631/337/100/1701</topic><topic>631/67/1059/99</topic><topic>Antagonism</topic><topic>Antineoplastic Agents - metabolism</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antitumor agents</topic><topic>Cell Line, Tumor</topic><topic>Chemotherapy</topic><topic>Chromatin</topic><topic>Chromatin - drug effects</topic><topic>Chromatin - genetics</topic><topic>Cisplatin</topic><topic>Cisplatin - metabolism</topic><topic>Cisplatin - pharmacology</topic><topic>Cytometry</topic><topic>Cytotoxicity</topic><topic>Daunorubicin</topic><topic>Daunorubicin - metabolism</topic><topic>Daunorubicin - pharmacology</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>DNA adducts</topic><topic>DNA Adducts - drug effects</topic><topic>DNA, Neoplasm - metabolism</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Interactions</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Mass spectrometry</topic><topic>Mass spectroscopy</topic><topic>multidisciplinary</topic><topic>Retention time</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Firouzi Niaki, Erfaneh</creatorcontrib><creatorcontrib>Van Acker, Thibaut</creatorcontrib><creatorcontrib>Imre, László</creatorcontrib><creatorcontrib>Nánási, Péter</creatorcontrib><creatorcontrib>Tarapcsák, Szabolcs</creatorcontrib><creatorcontrib>Bacsó, Zsolt</creatorcontrib><creatorcontrib>Vanhaecke, Frank</creatorcontrib><creatorcontrib>Szabó, Gábor</creatorcontrib><collection>SpringerOpen</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Science Journals</collection><collection>Biological Science Database</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Firouzi Niaki, Erfaneh</au><au>Van Acker, Thibaut</au><au>Imre, László</au><au>Nánási, Péter</au><au>Tarapcsák, Szabolcs</au><au>Bacsó, Zsolt</au><au>Vanhaecke, Frank</au><au>Szabó, Gábor</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interactions of Cisplatin and Daunorubicin at the Chromatin Level</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2020-01-24</date><risdate>2020</risdate><volume>10</volume><issue>1</issue><spage>1107</spage><pages>1107-</pages><artnum>1107</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>Unexpectedly, the widely used anticancer agents Cisplatin (Cis-Pt) and Daunorubicin (Dauno) exhibited cell type- and concentration-dependent synergy or antagonism in vitro . We attempted to interpret these effects in terms of the changes elicited by the drugs in the chromatin, the target held primarily responsible for the cytotoxicity of both agents. We measured the effect of Cis-Pt on the levels of Dauno in different cell compartments, the effect of Cis-Pt on Dauno-induced nucleosome eviction, and assessed the influence of Dauno on DNA platination in flow- and laser scanning cytometry as well as in laser ablation-inductively coupled plasma-mass spectrometry assays. We show that the two drugs antagonize each other through a decrease of interstrand crosslinks upon co-treatment with Dauno, and also via the diminished Dauno uptake in the presence of Cis-Pt, and both effects are observed already at low Dauno concentrations. At high Dauno concentrations synergy becomes dominant because histone eviction by Dauno intercalation into the DNA is enhanced in the presence of co-treatment with Cis-Pt. These interactions may have an impact on the efficacy of combination treatment protocols, considering the long retention time of DNA adducts formed by both agents.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>31980698</pmid><doi>10.1038/s41598-020-57702-7</doi><orcidid>https://orcid.org/0000-0002-0649-7228</orcidid><orcidid>https://orcid.org/0000-0002-1884-3853</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2045-2322
ispartof Scientific reports, 2020-01, Vol.10 (1), p.1107, Article 1107
issn 2045-2322
2045-2322
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6981277
source PubMed (Medline); Full-Text Journals in Chemistry (Open access); Publicly Available Content (ProQuest); Springer Nature - nature.com Journals - Fully Open Access
subjects 101/58
13/1
13/31
14/19
14/34
14/35
14/63
631/337/100/101
631/337/100/1701
631/67/1059/99
Antagonism
Antineoplastic Agents - metabolism
Antineoplastic Agents - pharmacology
Antitumor agents
Cell Line, Tumor
Chemotherapy
Chromatin
Chromatin - drug effects
Chromatin - genetics
Cisplatin
Cisplatin - metabolism
Cisplatin - pharmacology
Cytometry
Cytotoxicity
Daunorubicin
Daunorubicin - metabolism
Daunorubicin - pharmacology
Deoxyribonucleic acid
DNA
DNA adducts
DNA Adducts - drug effects
DNA, Neoplasm - metabolism
Dose-Response Relationship, Drug
Drug Interactions
Humanities and Social Sciences
Humans
Mass spectrometry
Mass spectroscopy
multidisciplinary
Retention time
Science
Science (multidisciplinary)
title Interactions of Cisplatin and Daunorubicin at the Chromatin Level
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T16%3A45%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interactions%20of%20Cisplatin%20and%20Daunorubicin%20at%20the%20Chromatin%20Level&rft.jtitle=Scientific%20reports&rft.au=Firouzi%20Niaki,%20Erfaneh&rft.date=2020-01-24&rft.volume=10&rft.issue=1&rft.spage=1107&rft.pages=1107-&rft.artnum=1107&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-020-57702-7&rft_dat=%3Cproquest_pubme%3E2344544885%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c474t-753497f29ea5dc51e2b8aa38916ca2b40e333ed8031c25bd462d0419d215dea83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2344544885&rft_id=info:pmid/31980698&rfr_iscdi=true